Josh Schimmer
Stock Analyst at Cantor Fitzgerald
(3.70)
# 774
Out of 4,981 analysts
138
Total ratings
47.58%
Success rate
8.23%
Average return
Main Sectors:
Stocks Rated by Josh Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGON CG Oncology | Reiterates: Overweight | $75 | $33.40 | +124.55% | 5 | Sep 8, 2025 | |
| DNLI Denali Therapeutics | Reiterates: Overweight | n/a | $14.19 | - | 3 | Sep 8, 2025 | |
| SEPN Septerna | Reiterates: Overweight | $25 | $14.28 | +75.07% | 4 | Sep 5, 2025 | |
| CABA Cabaletta Bio | Reiterates: Overweight | $15 | $1.84 | +715.22% | 2 | Sep 5, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $10 → $8 | $3.16 | +153.16% | 7 | Aug 8, 2025 | |
| BBIO BridgeBio Pharma | Reiterates: Overweight | $95 | $51.21 | +85.51% | 12 | Jul 29, 2025 | |
| TRVI Trevi Therapeutics | Initiates: Overweight | $25 | $8.25 | +203.03% | 1 | Jul 1, 2025 | |
| CMPS COMPASS Pathways | Downgrades: In-Line | $11 → $6 | $5.20 | +15.38% | 2 | Jun 23, 2025 | |
| ASND Ascendis Pharma | Maintains: Outperform | $260 → $280 | $195.58 | +43.16% | 4 | May 2, 2025 | |
| AARD Aardvark Therapeutics | Reiterates: Overweight | $50 | $8.50 | +488.24% | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $20 | $2.56 | +681.25% | 2 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $143.68 | +49.64% | 5 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $5 | $1.90 | +163.16% | 4 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $200 | $24.05 | +731.60% | 6 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $47.61 | -47.49% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.00 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $10.03 | +199.10% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.81 | - | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.75 | - | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $34.00 | +164.71% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.43 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $145.93 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $29.72 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $17.32 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.42 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $76.19 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 | $0.60 | +2,396.67% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $53 | $44.74 | +18.46% | 5 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $36.20 | +79.58% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $60 | $74.31 | -19.26% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $43 → $5 | $2.30 | +117.39% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $11 | $1.56 | +605.13% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $140 → $130 | $141.90 | -8.39% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $760 | $560.00 | +35.71% | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $15.73 | -4.64% | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $6.53 | +742.27% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.83 | +1,539.34% | 1 | Dec 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $1.14 | - | 4 | Dec 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $9.20 | - | 3 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $222 → $250 | $432.27 | -42.17% | 4 | Nov 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $83.10 | - | 2 | Jun 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $63.16 | - | 2 | May 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $4.18 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $16.49 | +33.45% | 1 | Nov 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $14.29 | - | 2 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $54.09 | - | 1 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $218.34 | -56.49% | 1 | Aug 17, 2017 |
CG Oncology
Sep 8, 2025
Reiterates: Overweight
Price Target: $75
Current: $33.40
Upside: +124.55%
Denali Therapeutics
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $14.19
Upside: -
Septerna
Sep 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $14.28
Upside: +75.07%
Cabaletta Bio
Sep 5, 2025
Reiterates: Overweight
Price Target: $15
Current: $1.84
Upside: +715.22%
Rocket Pharmaceuticals
Aug 8, 2025
Maintains: Overweight
Price Target: $10 → $8
Current: $3.16
Upside: +153.16%
BridgeBio Pharma
Jul 29, 2025
Reiterates: Overweight
Price Target: $95
Current: $51.21
Upside: +85.51%
Trevi Therapeutics
Jul 1, 2025
Initiates: Overweight
Price Target: $25
Current: $8.25
Upside: +203.03%
COMPASS Pathways
Jun 23, 2025
Downgrades: In-Line
Price Target: $11 → $6
Current: $5.20
Upside: +15.38%
Ascendis Pharma
May 2, 2025
Maintains: Outperform
Price Target: $260 → $280
Current: $195.58
Upside: +43.16%
Aardvark Therapeutics
Apr 1, 2025
Reiterates: Overweight
Price Target: $50
Current: $8.50
Upside: +488.24%
Mar 25, 2025
Maintains: Overweight
Price Target: $23 → $20
Current: $2.56
Upside: +681.25%
Feb 20, 2025
Reiterates: Overweight
Price Target: $215
Current: $143.68
Upside: +49.64%
Dec 20, 2024
Downgrades: In-Line
Price Target: $5
Current: $1.90
Upside: +163.16%
Dec 11, 2024
Reiterates: Overweight
Price Target: $200
Current: $24.05
Upside: +731.60%
Dec 11, 2024
Reiterates: Overweight
Price Target: $25
Current: $47.61
Upside: -47.49%
Dec 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.00
Upside: -
Oct 8, 2024
Reiterates: Overweight
Price Target: $30
Current: $10.03
Upside: +199.10%
Sep 23, 2024
Downgrades: Neutral
Price Target: n/a
Current: $6.81
Upside: -
Sep 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.75
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $90
Current: $34.00
Upside: +164.71%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.43
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $145.93
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $29.72
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $17.32
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.42
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $76.19
Upside: -
Aug 26, 2024
Maintains: Outperform
Price Target: $15
Current: $0.60
Upside: +2,396.67%
Aug 26, 2024
Maintains: Outperform
Price Target: $54 → $53
Current: $44.74
Upside: +18.46%
Aug 9, 2024
Reiterates: Overweight
Price Target: $65
Current: $36.20
Upside: +79.58%
Aug 8, 2024
Maintains: Overweight
Price Target: $50 → $60
Current: $74.31
Upside: -19.26%
Nov 10, 2023
Downgrades: In-Line
Price Target: $43 → $5
Current: $2.30
Upside: +117.39%
Jun 6, 2023
Maintains: Outperform
Price Target: $20 → $11
Current: $1.56
Upside: +605.13%
Nov 14, 2022
Downgrades: In-Line
Price Target: $140 → $130
Current: $141.90
Upside: -8.39%
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $560.00
Upside: +35.71%
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $15.73
Upside: -4.64%
Feb 2, 2021
Initiates: Outperform
Price Target: $55
Current: $6.53
Upside: +742.27%
Dec 29, 2020
Initiates: Outperform
Price Target: $30
Current: $1.83
Upside: +1,539.34%
Dec 9, 2019
Downgrades: In-Line
Price Target: n/a
Current: $1.14
Upside: -
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $9.20
Upside: -
Nov 16, 2018
Upgrades: Outperform
Price Target: $222 → $250
Current: $432.27
Upside: -42.17%
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $83.10
Upside: -
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $63.16
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $4.18
Upside: -
Nov 7, 2017
Initiates: Outperform
Price Target: $22
Current: $16.49
Upside: +33.45%
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $14.29
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $54.09
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: $95
Current: $218.34
Upside: -56.49%